Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges

Front Pharmacol. 2024 Jan 9:14:1260276. doi: 10.3389/fphar.2023.1260276. eCollection 2023.

Abstract

Over the past two decades, Next-Generation Sequencing (NGS) has revolutionized the approach to cancer research. Applications of NGS include the identification of tumor specific alterations that can influence tumor pathobiology and also impact diagnosis, prognosis and therapeutic options. Pharmacogenomics (PGx) studies the role of inheritance of individual genetic patterns in drug response and has taken advantage of NGS technology as it provides access to high-throughput data that can, however, be difficult to manage. Machine learning (ML) has recently been used in the life sciences to discover hidden patterns from complex NGS data and to solve various PGx problems. In this review, we provide a comprehensive overview of the NGS approaches that can be employed and the different PGx studies implicating the use of NGS data. We also provide an excursus of the ML algorithms that can exert a role as fundamental strategies in the PGx field to improve personalized medicine in cancer.

Keywords: drug efficacy; drug repurposing; drug toxicity; machine learning; omics; pharmacogenomics; targeted therapy.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work is founded by the Progetto di Ricerca Finalizzata Regione Friuli Venezia Giulia Anno 2021 LR 13/2021, art. 8, c. 28-30 to GT (CUP J35F21002710002 of Centro di Riferimento Oncologico di Aviano, IRCCS), and by the Italian Ministry of Health (Ricerca Corrente).